• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions.

作者信息

Lebel Eyal, Ben-Yehuda Dina, Bohbot Emilie, Dranitzki Zvi, Shalit Meir, Tal Yuval

机构信息

Department of Hematology, Hadassah University Medical Center, Jerusalem, Israel.

Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah University Medical Center, Jerusalem, Israel.

出版信息

J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):1000-2. doi: 10.1016/j.jaip.2016.05.013. Epub 2016 Jun 18.

DOI:10.1016/j.jaip.2016.05.013
PMID:27329468
Abstract
摘要

相似文献

1
Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions.利妥昔单抗超敏反应:7例严重、近乎致命反应患者中的53次成功脱敏。
J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):1000-2. doi: 10.1016/j.jaip.2016.05.013. Epub 2016 Jun 18.
2
Rituximab desensitization in three patients with severe rituximab allergy.三名严重利妥昔单抗过敏患者的利妥昔单抗脱敏治疗
Curr Probl Cancer. 2017 Sep-Oct;41(5):349-354. doi: 10.1016/j.currproblcancer.2017.07.003. Epub 2017 Jul 27.
3
Rapid Drug Desensitization With Rituximab in 24 Cases: A Single-Center Experience.利妥昔单抗用于24例患者的快速药物脱敏:单中心经验
J Investig Allergol Clin Immunol. 2019;29(6):468-470. doi: 10.18176/jiaci.0445. Epub 2019 Sep 18.
4
Desensitization to rituximab in a multidisciplinary setting.多学科环境下对利妥昔单抗的脱敏治疗
Int J Clin Pharm. 2015 Oct;37(5):744-8. doi: 10.1007/s11096-015-0136-x. Epub 2015 May 22.
5
Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms.利妥昔单抗过敏反应:评估、脱敏及潜在机制。
J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1564-1571. doi: 10.1016/j.jaip.2017.08.004.
6
Rituximab hypersensitivity in IgG4-related disease: successful desensitization in a patient with IgG4 rheumatoid factor.IgG4相关疾病中的利妥昔单抗超敏反应:1例伴有IgG4类风湿因子患者的成功脱敏治疗
Int J Rheum Dis. 2017 Feb;20(2):276-279. doi: 10.1111/1756-185X.13021. Epub 2016 Dec 30.
7
Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.抗 mAb 过敏反应:23 例患者共 105 次脱敏治疗,从评估到治疗。
J Allergy Clin Immunol. 2009 Dec;124(6):1259-66. doi: 10.1016/j.jaci.2009.09.009.
8
[Castleman's disease: Rapid desensitization for hypersensitivity reaction to rituximab].[Castleman病:利妥昔单抗超敏反应的快速脱敏治疗]
Rev Med Interne. 2016 Jun;37(6):433-6. doi: 10.1016/j.revmed.2015.08.011. Epub 2015 Sep 26.
9
Rituximab desensitization in two patients with muscle-specific kinase myasthenia gravis.两名肌肉特异性激酶重症肌无力患者的利妥昔单抗脱敏治疗
Muscle Nerve. 2019 Nov;60(5):E35-E37. doi: 10.1002/mus.26691. Epub 2019 Sep 11.
10
Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.来那度胺脱敏治疗5例多发性骨髓瘤患者的迟发型超敏反应
Br J Haematol. 2014 Oct;167(1):127-31. doi: 10.1111/bjh.12925. Epub 2014 May 14.

引用本文的文献

1
Retrospective analysis of rapid drug desensitization with biologic agents: A single center experience.生物制剂快速药物脱敏的回顾性分析:单中心经验
Clin Transl Allergy. 2024 Oct;14(10):e12397. doi: 10.1002/clt2.12397.
2
Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement.实用静脉内快速药物脱敏和去标签标准:WAO委员会声明
World Allergy Organ J. 2022 May 31;15(6):100640. doi: 10.1016/j.waojou.2022.100640. eCollection 2022 Jun.
3
Rituximab Hypersensitivity: From Clinical Presentation to Management.
利妥昔单抗超敏反应:从临床表现到管理
Front Pharmacol. 2020 Sep 8;11:572863. doi: 10.3389/fphar.2020.572863. eCollection 2020.
4
Desensitization to biological agents used in rheumatology.对风湿病学中使用的生物制剂的脱敏作用。
Reumatologia. 2020;58(1):25-33. doi: 10.5114/reum.2020.93510. Epub 2020 Feb 28.
5
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.在美国复发或难治性多发性骨髓瘤患者中实施达雷妥尤单抗早期准入治疗方案的结果。
Cancer. 2018 Nov 15;124(22):4342-4349. doi: 10.1002/cncr.31706. Epub 2018 Nov 5.